Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Sept. 19, 2024 /PRNewswire/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However, there's still a lot of work to do in the war on cancer, with the 2024 World Cancer Congress in Geneva highlighting several issues, such as artificial intelligence (AI), conflict zones and crisis care taking center stage at the gathering. Plenty of support for research continues to roll in, with philanthropists recently giving a historic $150 million for pancreatic cancer research to City of Hope, while Stanford experts are calling for more massive federal funding increases to cancer research. At the research level, several players are making significant progress in oncology, with recent developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), Lantheus Holdings, Inc. (NASDAQ: LNTH), Sutro Biopharma, Inc. (NASDAQ: STRO), and Zymeworks Inc. (NASDAQ: ZYME).